131 related articles for article (PubMed ID: 37817474)
1. Association of plasma advanced glycation end-products and their soluble receptor with type 2 diabetes among Chinese adults.
Chen L; Wang Q; Lv Y; Xu W; Jiang G; Li Y; Luo P; He R; Liu L
Diabetes Metab Res Rev; 2024 Feb; 40(2):e3735. PubMed ID: 37817474
[TBL] [Abstract][Full Text] [Related]
2. Association of four differently processed diets with plasma and urine advanced glycation end products and serum soluble receptor for advanced glycation end products concentration in healthy dogs.
Bridglalsingh S; Archer-Hartmann S; Azadi P; Barbier de La Serre C; Remillard RL; Sunvold GD; Bartges JW
J Anim Physiol Anim Nutr (Berl); 2024 May; 108(3):735-751. PubMed ID: 38279966
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
[TBL] [Abstract][Full Text] [Related]
4. Circulating Ligands of the Receptor for Advanced Glycation End Products and the Soluble Form of the Receptor Modulate Cardiovascular Cell Apoptosis in Diabetes.
Tsoporis JN; Hatziagelaki E; Gupta S; Izhar S; Salpeas V; Tsiavou A; Rigopoulos AG; Triantafyllis AS; Marshall JC; Parker TG; Rizos IK
Molecules; 2020 Nov; 25(22):. PubMed ID: 33182705
[TBL] [Abstract][Full Text] [Related]
5. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
[TBL] [Abstract][Full Text] [Related]
6. Soluble receptor for advanced glycation end products is associated with in-stent restenosis in patients with type 2 diabetes with drug-eluting coronary stents.
Park HJ; Seo SM; Shin WS; Kim HY; Choi YS; Koh YS; Youn SG; Park MW; Chang K; Kim PJ; Jung HO; Baek SH; Chung WS; Seung KB; Yoo KD
Coron Artery Dis; 2011 Jan; 22(1):12-7. PubMed ID: 21197704
[TBL] [Abstract][Full Text] [Related]
7. Circulating Advanced Glycation End Products and Their Soluble Receptors in Relation to All-Cause and Cardiovascular Mortality: A Systematic Review and Meta-analysis of Prospective Observational Studies.
Sharifi-Zahabi E; Sharafabad FH; Abdollahzad H; Malekahmadi M; Rad NB
Adv Nutr; 2021 Dec; 12(6):2157-2171. PubMed ID: 34139010
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study.
Sabbatinelli J; Castiglione S; Macrì F; Giuliani A; Ramini D; Vinci MC; Tortato E; Bonfigli AR; Olivieri F; Raucci A
Cardiovasc Diabetol; 2022 Jun; 21(1):95. PubMed ID: 35668468
[TBL] [Abstract][Full Text] [Related]
9. Dietary protein intake and circulating advanced glycation end product/receptor for advanced glycation end product concentrations in the Health, Aging, and Body Composition Study.
Brinkley TE; Semba RD; Kritchevsky SB; Houston DK;
Am J Clin Nutr; 2020 Dec; 112(6):1558-1565. PubMed ID: 33301008
[TBL] [Abstract][Full Text] [Related]
10. Advanced glycation end products (AGEs) and their soluble receptors (sRAGE) as early predictors of reno-vascular complications in patients with uncontrolled type 2 diabetes mellitus.
Farhan SS; Hussain SA
Diabetes Metab Syndr; 2019; 13(4):2457-2461. PubMed ID: 31405660
[TBL] [Abstract][Full Text] [Related]
11. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer.
Jiao L; Taylor PR; Weinstein SJ; Graubard BI; Virtamo J; Albanes D; Stolzenberg-Solomon RZ
Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1430-8. PubMed ID: 21527578
[TBL] [Abstract][Full Text] [Related]
12. Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.
Yu Y; Hanssen KF; Kalyanaraman V; Chirindel A; Jenkins AJ; Nankervis AJ; Torjesen PA; Scholz H; Henriksen T; Lorentzen B; Garg SK; Menard MK; Hammad SM; Scardo JA; Stanley JR; Wu M; Basu A; Aston CE; Lyons TJ
BJOG; 2012 Nov; 119(12):1512-20. PubMed ID: 22900949
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum levels of advanced glycation end products and their monocyte receptors in patients with type 2 diabetes.
Su XD; Li SS; Tian YQ; Zhang ZY; Zhang GZ; Wang LX
Arch Med Res; 2011 Oct; 42(7):596-601. PubMed ID: 22100610
[TBL] [Abstract][Full Text] [Related]
14. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study.
Melin EO; Dereke J; Hillman M
Lipids Health Dis; 2020 Oct; 19(1):223. PubMed ID: 33054750
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end products, leukocyte telomere length, and mitochondrial DNA copy number in patients with coronary artery disease and alterations of glucose homeostasis: From the GENOCOR study.
Vecoli C; Basta G; Borghini A; Gaggini M; Del Turco S; Mercuri A; Gastaldelli A; Andreassi MG
Nutr Metab Cardiovasc Dis; 2022 May; 32(5):1236-1244. PubMed ID: 35260310
[TBL] [Abstract][Full Text] [Related]
16. Soluble Receptor for Advanced Glycation End-products (sRAGE) and Colorectal Cancer Risk: A Case-Control Study Nested within a European Prospective Cohort.
Aglago EK; Rinaldi S; Freisling H; Jiao L; Hughes DJ; Fedirko V; Schalkwijk CG; Weiderpass E; Dahm CC; Overvad K; Eriksen AK; Kyrø C; Boutron-Ruault MC; Rothwell JA; Severi G; Katzke V; Kühn T; Schulze MB; Aleksandrova K; Masala G; Krogh V; Panico S; Tumino R; Naccarati A; Bueno-de-Mesquita B; van Gils CH; Sandanger TM; Gram IT; Skeie G; Quirós JR; Jakszyn P; Sánchez MJ; Amiano P; Huerta JM; Ardanaz E; Johansson I; Harlid S; Perez-Cornago A; Mayén AL; Cordova R; Gunter MJ; Vineis P; Cross AJ; Riboli E; Jenab M
Cancer Epidemiol Biomarkers Prev; 2021 Jan; 30(1):182-192. PubMed ID: 33082206
[TBL] [Abstract][Full Text] [Related]
17. Association between Advanced Glycation End Products, Soluble RAGE Receptor, and Endothelium Dysfunction, Evaluated by Circulating Endothelial Cells and Endothelial Progenitor Cells in Patients with Mild and Resistant Hypertension.
Gryszczyńska B; Budzyń M; Begier-Krasińska B; Osińska A; Boruczkowski M; Kaczmarek M; Bukowska A; Iskra M; Kasprzak MP
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412635
[TBL] [Abstract][Full Text] [Related]
18. Critical Appraisal of Advanced Glycation End Products (AGEs) and Circulating Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients.
Assiri AMA; Kamel HFM; ALrefai AA
Med Sci (Basel); 2018 May; 6(2):. PubMed ID: 29789493
[TBL] [Abstract][Full Text] [Related]
19. Advanced glycation end-products and its soluble receptor are not independent predictors of incident dysglycaemia or metabolic syndrome in women with polycystic ovary syndrome: a prospective observational study.
Tong YW; Ko JKY; Lam KSL; Tam S; Lee VCY; Ho PC; Ng EHY; Li RHW
Reprod Biol Endocrinol; 2023 May; 21(1):41. PubMed ID: 37165411
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes.
Kopytek M; Ząbczyk M; Mazur P; Undas A; Natorska J
Cardiovasc Diabetol; 2020 Jun; 19(1):92. PubMed ID: 32552684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
